@article{ca0fc98ba4ef48fd90fa1338191c1f6a,
title = "Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde",
author = "Michael Wysota and Saeed Asiry and Yitzhak Goldstein and Sequist, \{Lecia V.\} and Samer Khader and Balazs Halmos",
note = "Funding Information: Disclosure: Dr. Sequist reports receiving grants and consulting fees from AstraZeneca and Genentech; consulting fees from Janssen; and grants from Novartis , Boehringer Ingelheim , Merrimack, LOXO, and Blueprint Medicines outside of the submitted work. Dr. Halmos reports receiving grants and personal fees from Merck , Bristol-Myers Squibb , AstraZeneca , Boehringer Ingelheim , Novartis , Amgen , Guardant Health , and Pfizer ; grants from Eli Lilly , Foundation Medicine , AbbVie , Advaxis, Blueprint, Mirati, and GlaxoSmithKline ; and personal fees from Genentech and TPT outside of the submitted work. The remaining authors declare no conflict of interest. ",
year = "2021",
month = feb,
doi = "10.1016/j.jtocrr.2020.100128",
language = "English (US)",
volume = "2",
journal = "JTO Clinical and Research Reports",
issn = "2666-3643",
publisher = "Elsevier Inc.",
number = "2",
}